Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterIn the past 20 trading days, ABBV has been trading in a range between $190.14 and $169.20 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
ABBV is trading between resistance at $193.61 about 0% to the upside and support at $182.93 -5% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $203.87, about a 6% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
AbbVie Inc $ABBV entered a Green zone 9 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $202.3279, a potential upside of 6.15% from the recent price of 190.60. The stock is trading 7.75% (potential upside) below its 52 week high of $205.38 and 27.44 % (potential downside) above its 52 week low of $149.56 - based on the recent price.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers' consultative and clinical skills Innovative curriculum will empower providers to deliver outcomes with excellence and support loyal patient relationships IRVINE, Calif. , Feb. 12, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new state-of-the-art training centers in the U.S. expanding access to high-quality, tailored training to licensed aesthetics providers. Source: PRNewsWire Wed, 12 Feb 2025 08:30:00 -0500 Sentiment: Neutral |
These Stocks Missed on Earnings, But Will Rebound Next Quarter MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Source: MarketBeat Mon, 10 Feb 2025 08:35:14 -0500 Sentiment: Neutral |
3 Fabulous Dividend Stocks to Buy in February February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Source: The Motley Fool Sun, 09 Feb 2025 14:30:00 -0500 Sentiment: Positive |
3 Dividend Stocks to Double Up on Right Now What's better than a good thing? More of a good thing. Source: The Motley Fool Sun, 09 Feb 2025 05:43:00 -0500 Sentiment: Positive |
These 2 Dividend Stocks Are Absolute Bargains Right Now Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excellent income stocks when they seem to be trading at attractive valuations, which isn't always easy to find since such corporations are in high demand. Source: The Motley Fool Sat, 08 Feb 2025 08:30:00 -0500 Sentiment: Positive |
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.